Priveterra Acquisition Corp. (NASDAQ:PMGM) announced this afternoon that its special meeting, intended to approve its combination with AEON Biopharma, has been adjourned for the seventh consecutive time.
Given the SPAC’s completion deadline of August 11, it is unlikely that this will be the last adjournment we will see for this completion vote.
Initially scheduled for noon today, the meeting has now been pushed back until June 30 at 4:00 p.m. Priveterra continues to reiterate its commitment to utilizing the extended time during the postponement to further engage with its shareholders.
The deal with AEON Biopharma includes a $40 million minimum cash condition, half of which has already been secured through a $20 million commitment from existing AEON investors at $7 per share. But, Priveterra’s trust, originally totaling $276 million, has been reduced to about $20.3 million after seeing 92.7% of shares redeemed in earlier votes.
Priveterra inked its $201.8 million business combination with drug developer AEON on December 13. Irvine, California-based AEON is working on an injection-based migraine treatment to compete with Botox for chronic and frequent sufferers.
At the SPAC of Dawn It has clearly taken some time for SPACs to break out from their niche, but SPACs and de-SPACs are suddenly everywhere in current events. As the Russian invasion of Ukraine drags on, one of the most prolific SPAC teams has stepped forward with a letter of intent to take Ukraine’s...
Live Oak Acquisition Corp. V (NASDAQ:LOKVU) has filed for a $200 million IPO that brings another serial SPAC team back to the mix for a generalist search but with a pair of technology deals already in their pocket. The new S-1 also puts Santander on the board for the 2025 SPAC market after it made...
CH4 Natural Solutions (NYSE:MTNE.U) has filed for a $250 million SPAC to bring both the Riverstone sponsor team and underwriter Citigroup back to the market for 2025. The team secured notably sponsor-friendly terms for the vehicle and will not overfund its trust. In fact, along with fellow Friday filer Live Oak V (NASDAQ:LOKVU), these two...
At the SPAC of Dawn Amid a restive market, SPACs have front-loaded their business this week with three of their four votes set for today and tomorrow. One of these is a completion vote, in which Bowen (NASDAQ:BOWN) will try and secure shareholder approval for its combination with Shenzhen Qianzhi BioTechnology just after having gained...
Terms Tracker for the Week Ending January 10, 2025 Welcome to our weekly column where we discuss the findings from our IPO terms tracker based on the previous week’s pricings. This was the first full week in January and the first non-holiday week since December 23rd. All the same, 2025 has started with a bang...